Research Topics
Species | Matthew EllisSummaryAffiliation: Washington University School of Medicine Country: USA Publications
| Collaborators
|
Detail Information
Publications
Letrozole in the treatment of breast cancerHeather S Shaw
Multidisciplinary Breast Program, Duke University Medical Center, Box 3381, Durham, NC 27710, USA
Expert Opin Pharmacother 3:607-17. 2002..The object of this review is to provide a reference source on the biochemical, pharmacological and clinical properties of letrozole for clinicians to consider both established and future indications...- Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathwayRobert J Crowder
Department of Medicine, Division of Oncology, Washington University School of Medicine and Siteman Cancer Center, St Louis, Missouri, USA
Breast Cancer Res 7:212-4. 2005.... - Femara and the future: tailoring treatment and combination therapies with FemaraMatthew Ellis
Medical Oncology, Washington University, 660 Euclid Ave, Campus Box 8056, St Louis, MO 63110, USA
Breast Cancer Res Treat 105:105-15. 2007..Microarray gene profiling studies, designed to detect letrozole-responsive targets, are currently under way to understand how the use of the drug can be tailored more efficiently to specific patient needs... - Letrozole in the neoadjuvant setting: the P024 trialMatthew J Ellis
Medical Oncology, Washington University, Campus Box 8056, 660 Euclid Ave, St Louis, MO 63110, USA
Breast Cancer Res Treat 105:33-43. 2007..0009). Thus, neoadjuvant letrozole is safe and superior to tamoxifen in the treatment of postmenopausal women with HR+ locally advanced breast cancer... - Neoadjuvant endocrine therapy for locally advanced breast cancerCynthia X Ma
Department of Oncology, Siteman Comprehensive Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
Semin Oncol 33:650-6. 2006..In this review, we outline the rationale for preoperative endocrine therapy, and consider predictive models for endocrine therapy responsiveness in this setting... - Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozoleMatthew J Ellis
Siteman Comprehensive Cancer Center, Washington University School of Medicine, Campus Box 8056, 660 S Euclid Ave, St Louis, MO 63110, USA
J Clin Oncol 24:3019-25. 2006.... - Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristicsMatthew J Ellis
Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Ave, St Louis, MO 63119, USA
J Natl Cancer Inst 100:1380-8. 2008.... - Overcoming endocrine therapy resistance by signal transduction inhibitionMatthew Ellis
Siteman Cancer Center, Washington University, St Louis, Missouri 63110, USA
Oncologist 9:20-6. 2004..With a number of phase III clinical trials now under way, major advances in the endocrine treatment of advanced disease are possible... - Predicting endocrine therapy responsiveness in breast cancerCynthia X Ma
Section of Medical Oncology, Division of Oncology, Department of Internal Medicine, Siteman Comprehensive Cancer Center, Washington University School of Medicine, St Louis, Missouri 63110, USA
Oncology (Williston Park) 23:133-42. 2009.... - Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trialsYu Tao
Siteman Cancer Center and Washington University in St. Louis, Campus Box 8506, 660 South Euclid Avenue, St. Louis, MO 63110, USA
J Steroid Biochem Mol Biol 95:91-5. 2005.... - PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancerFarrokh Dehdashti
Division of Nuclear Medicine, Edward Mallinckrodt Institute of Radiology, St Louis, MO 63110, USA
Breast Cancer Res Treat 113:509-17. 2009.... - Estrogen receptor expression and sensitivity to paclitaxel in breast cancerMichele K Dougherty
Lombardi Cancer Center, Department of Oncology, Georgetown University Medical Center, Washington, DC, USA
Cancer Biol Ther 3:460-7. 2004..These data suggest that measurements of tumor proliferation may provide more accurate predictive markers for the benefits of adjuvant paclitaxel than ERalpha analysis... - The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancersP Kelly Marcom
Siteman Comprehensive Cancer Center, Washington University School of Medicine, 660 South Euclid Ave, Campus Box 8056, St Louis, MO, USA
Breast Cancer Res Treat 102:43-9. 2007..The efficacy of the aromatase inhibitor letrozole in combination with trastuzumab was therefore tested in a Phase 2 study... - PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancerRobert J Crowder
Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri 63110, USA
Cancer Res 69:3955-62. 2009..Our results suggest that PI3K inhibitors should target both p110alpha and p110beta catalytic subunits, whether wild-type or mutant, and be combined with endocrine therapy for maximal efficacy when treating ER(+) breast cancer... - Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression statusMatthew J Ellis
Duke University Comprehensive Cancer Center, Campus Box 8056, 660 South Euclid, Durham, NC 27710, USA
Cancer Res 63:6523-31. 2003.... - Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized studyMatthew J Ellis
Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO 63110, USA
JAMA 302:774-80. 2009..Estrogen deprivation therapy with aromatase inhibitors has been hypothesized to paradoxically sensitize hormone-receptor-positive breast cancer tumor cells to low-dose estradiol therapy... - A longitudinal study of factors associated with perceived risk of recurrence in women with ductal carcinoma in situ and early-stage invasive breast cancerYing Liu
Division of Health Behavior Research, Department of Internal Medicine, Washington University School of Medicine, St Louis, MO 63108, USA
Breast Cancer Res Treat 124:835-44. 2010..Educating early-stage breast cancer patients about their actual risk could result in more realistic recurrence-risk perceptions, and increasing social support could help alleviate anxiety associated with exaggerated risk perceptions... - Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trialMatthew J Ellis
Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63119, USA
Breast Cancer Res Treat 116:371-8. 2009..Expression of aromatase by malignant breast epithelial cells and/or the surrounding stroma implies local estrogen production that could influence the outcome of endocrine therapy for breast cancer... - Therapy related acute myeloid leukemia in breast cancer survivors, a population-based studyMike G Martin
Division of Oncology, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8007, Saint Louis, MO 63110, USA
Breast Cancer Res Treat 118:593-8. 2009..This association maybe explained by either greater chemotherapy exposure or an interaction between therapy and genetic predisposition... - Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current dataMatthew J Ellis
Siteman Comprehensive Cancer Center and Washington University School of Medicine, St Louis, MO 63110, USA
Curr Med Res Opin 22:2479-87. 2006..This review will compare the current available efficacy, safety, and cost-effectiveness data for AIs in the initial adjuvant and switch adjuvant settings... - A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasiaVered Stearns
Breast Cancer Program, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, D.C, USA
Clin Cancer Res 10:7583-91. 2004..Further investigations must overcome logistical obstacles to accrual, and they must focus on approaches to maximize tissue collection and to incorporate genomic analysis of target lesions... - Successful targeting of ErbB2 receptors-is PTEN the key?Robert J Crowder
Department of Medicine, Division of Oncology, Washington University School of Medicine and Siteman Cancer Center, Campus Box 8056, 660 South Euclid Avenue, St. Louis, MO 63110, USA
Cancer Cell 6:103-4. 2004..Resistance to trastuzumab occurs when PTEN function is lost, suggesting that PTEN activation is a critical component of the therapeutic effect... - A luminal breast cancer genome atlas: progress and barriersMatthew J Ellis
Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO 63119, USA
J Steroid Biochem Mol Biol 106:125-9. 2007.... - Neoadjuvant endocrine therapy as a drug development strategyMatthew J Ellis
Washington University School of Medicine, St Louis, Missouri, USA
Clin Cancer Res 10:391S-5S. 2004..However, the optimal clinical investigative approaches, analytical techniques, and appropriate surrogate end points have yet to be identified and are the subject of several ongoing or planned clinical studies... - Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancerMatthew J Ellis
Department of Medicine, Washington University School of Medicine, St Louis, MO 63119, USA
Breast Cancer Res Treat 119:379-90. 2010..Nonetheless, as with other recent studies, a favorable interaction between PIK3CA KD mutation and prognosis was detected. The mechanism for the favorable prognostic impact of PIK3CA mutation status therefore remains unexplained... - Importance of correlative science in advancing hormonal therapy and a new clinical paradigm for neoadjuvant therapyMatthew J Ellis
Washington University School of Medicine, Section of Medical Oncology and Breast Cancer Program, St Louis, Missouri, USA
Ann Surg Oncol 11:9S-17S. 2004..Ongoing investigations are examining gene expression profile changes associated with neoadjuvant endocrine therapy, as well as inhibitors of growth factor signaling that may modulate tamoxifen resistance... - Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trialRebecca Aft
Department of Surgery, Washington University School of Medicine, St Louis, MO 63110, USA
Lancet Oncol 11:421-8. 2010..The aim of our study was to assess the effect of zoledronic acid on clearance of disseminated tumour cells (DTCs) from the bone marrow in women undergoing neoadjuvant chemotherapy for breast cancer... - Neoadjuvant endocrine therapy for breast cancerJane S Chawla
Division of Oncology, Department of Medicine, Washington University, 660 South Euclid Avenue, St Louis, MO 63110, USA
Surg Oncol Clin N Am 19:627-38. 2010.... - High prevalence of low vitamin D and musculoskeletal complaints in women with breast cancerNicola Napoli
Division of Bone and Mineral Diseases at Washington University School of Medicine, St Louis, Missouri, USA
Breast J 16:609-16. 2010..Future studies may be needed to establish the contribution of low vitamin D, if any, on the prevalence of musculoskeletal pains in women on AIs... - "I'm pregnant and I have breast cancer"Michael J Naughton
Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
BMC Cancer 7:93. 2007..There is general consensus that both surgery and chemotherapy are relatively safe after the first trimester of pregnancy. It is generally agreed that therapeutic radiation, if necessary, should be delayed until completion of pregnancy... - Genome remodelling in a basal-like breast cancer metastasis and xenograftLi Ding
The Genome Center at Washington University, St Louis, Missouri 63108, USA
Nature 464:999-1005. 2010..The differential mutation frequencies and structural variation patterns in metastasis and xenograft compared with the primary tumour indicate that secondary tumours may arise from a minority of cells within the primary tumour... - Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignanciesPaula M Fracasso
Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA
Cancer Chemother Pharmacol 63:451-8. 2009..To determine the maximum tolerated dose, dose-limiting toxicity (DLT), and pharmacokinetics of weekly docosahexaenoic acid-paclitaxel (DHA-paclitaxel), a taxane fatty acid conjugate... - Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statementSteven E Come
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
Clin Cancer Res 10:327S-330S. 2004 - Improving outcomes for patients with hormone receptor-positive breast cancer: back to the drawing boardMatthew J Ellis
J Natl Cancer Inst 100:159-61. 2008 - HER2 and response to paclitaxel in node-positive breast cancerDaniel F Hayes
Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor 48109, USA
N Engl J Med 357:1496-506. 2007..We hypothesized that HER2 positivity predicts a benefit from adjuvant doxorubicin doses above standard levels, from the addition of paclitaxel after adjuvant chemotherapy with doxorubicin plus cyclophosphamide, or from both... - "PIKing" the winner for phosphatidylinositol 3-kinase inhibitors in ErbB2-positive breast cancer: let's not "PTENed" it's easy!Matthew J Ellis
Clin Cancer Res 13:5661-2. 2007 - Role of biologic markers in patient selection and application to disease preventionMitch Dowsett
Joint Institute of Cancer Research/Royal Marsden NHS Trust, Academic Department of Biochemistry, London, United Kingdom
Am J Clin Oncol 26:S34-9. 2003..Gene expression profiling (microarray analysis), i.e., genomic and proteomic studies, will probably advance the discovery of new biomarkers for breast cancer prevention and treatment... - Breast cancer gene expression analysis--the case for dynamic profilingMatthew J Ellis
Duke University Breast Cancer Program, Duke University Medical Center, DUMC PO Box 3446, Durham, NC 27710, USA
Adv Exp Med Biol 532:223-34. 2003..Using breast cancer endocrine therapy as an example our initial approaches to dynamic profiling will be described... - Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effectMatthew J Ellis
Breast Cancer Program, DUMC, Duke University, PO Box 3446, Durham, NC 27710, USA
J Steroid Biochem Mol Biol 86:301-7. 2003..When enough profiles have been generated it should be possible to detect complex interaction patterns that correctly reclassify ER+ disease into treatment responsive and resistant categories with high probability... - Dramatic response of choroidal metastases from breast cancer to a combination of trastuzumab and vinorelbineZee-Wan Wong
National Cancer Center, Singapore
Breast J 10:54-6. 2004.... - Neoadjuvant endocrine therapy for breast cancer: an overlooked option?Zee-Wan Wong
National Cancer Centre, Singapore
Oncology (Williston Park) 18:411-20; discussion 421, 424, 429 passim. 2004.... - Circulating tumor cells, disease progression, and survival in metastatic breast cancerMassimo Cristofanilli
Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
N Engl J Med 351:781-91. 2004..We tested the hypothesis that the level of circulating tumor cells can predict survival in metastatic breast cancer... - Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignanciesNeil L Spector
Department of Discovery Medicine and Clinical Pharmacology, GlaxoSmithKline, Five Moore Dr, Research Triangle Park, NC 27709 3398, USA
J Clin Oncol 23:2502-12. 2005..This was a pilot study to assess the biologic effects of lapatinib on various tumor growth/survival pathways in patients with advanced ErbB1 and/or ErbB2-overexpressing solid malignancies... - Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomasHoward A Burris
The Sarah Cannon Research Institute, 250 25th Avenue N, Suite 110, Nashville, TN 37203, USA
J Clin Oncol 23:5305-13. 2005.... - Neoadjuvant endocrine therapy for breast cancer: more questions than answersMatthew J Ellis
J Clin Oncol 23:4842-4. 2005 - The molecular portraits of breast tumors are conserved across microarray platformsZhiyuan Hu
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
BMC Genomics 7:96. 2006..To overcome this problem we used publicly available breast cancer gene expression data sets and a novel approach to data fusion, in order to validate a new breast tumor intrinsic list... - Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survivalDaniel F Hayes
Department of Internal Medicine and the Comprehensive Cancer Center, University of Michigan Health and Hospital System, Ann Arbor, Michigan 48109, USA
Clin Cancer Res 12:4218-24. 2006..In this study, additional follow-up data and CTC levels at subsequent follow-up visits were evaluated... - DASH: a novel analysis method for molecular dynamics simulation data. Analysis of ligands of PPAR-gammaDavid W Salt
Department of Mathematics, Lion Terrace, Buckingham Building, University of Portsmouth, Portsmouth, PO1 3HE, UK
J Med Chem 48:3214-20. 2005..DASH was compared with Ward's hierarchical cluster analysis method. The results show that DASH analysis is as good as Ward analysis in some areas (e.g. conformation identification) and is superior in others (e.g. speed and input size)... - Functional analysis of the breast cancer genomeMatthew J Ellis
J Clin Oncol 24:1649-50. 2006